Skip to main content
MedPathMedPath Home
Clinical Trials/NCT04157569
NCT04157569
Recruiting
Not Applicable

Monitoring Circulating Tumor DNA After Chemotherapy in Elderly Patients With Acute Leukemia

Navy General Hospital, Beijing1 site in 1 country200 target enrollmentStarted: November 5, 2019Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAcute Leukemia

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
Navy General Hospital, Beijing
Enrollment
200
Locations
1
Primary Endpoint
cumulative incidence of relapse(CIR)
OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

This study will monitor CtDNA After Chemotherapy in Elderly Patients With AL

Detailed Description

This study will use droplet digital PCR (ddPCR) method to quantify peripheral blood plasma mutant allele frequency (MAF) in elderly acute leukemia patients after chemotherapy to evaluate the clinical value of CtDNA .

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
60 Years to 100 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Written informed consent
  • •not pregnant female
  • •patients \>=60 years old
  • •Diagnosis of acute leukemia

Exclusion Criteria

  • •Pregnancy
  • •HIV positive
  • •patients \>=100 years old

Outcomes

Primary Outcomes

cumulative incidence of relapse(CIR)

Time Frame: through study completion, an average of 1 year

cumulative incidence of relapse

Secondary Outcomes

  • overall survival (OS)(through study completion, an average of 2 years)

Investigators

Sponsor
Navy General Hospital, Beijing
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Liren Qian

Principal Investigator

Navy General Hospital, Beijing

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract CarcinomaBiliary Tract Cancer
NCT06171321Shanghai East Hospital94
Recruiting
Not Applicable
ctDNA Monitoring in Early Breast CancerBreast Cancer
NCT04353557Geneplus-Beijing Co. Ltd.200
Terminated
Phase 2
Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast CancerHER2-negative Metastatic Breast Cancer
NCT04720729Institut Curie160
Unknown
Not Applicable
Circulating Tumor DNA in Surgical Lung Cancer PatientsLung Neoplasms
NCT03081741Shenzhen Gene Health Bio Tech Co., Ltd.500
Recruiting
Phase 3
CtDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: a Single-center, Randomized, Controlled StudyColon CancerColon Cancer (stage II & III)
NCT06609551Zhejiang Cancer Hospital312